Highest-materiality recent filing
BIO-key International dismisses Bush & Associates, engages M&K CPAS as new auditor
Audit Committee approved engagement of M&K CPAS, PLLC on July 2, 2026; Bush & Associates dismissed on July 7, 2026.
BIO-key regains Nasdaq compliance; trading resumes July 8 after hearing panel decision
Nasdaq Hearings Panel determined BIO-key regained compliance with minimum bid price and SEC filing requirements.
BIO-key receives Nasdaq notice for delayed 10-Q filing; delisting hearing set for June 16
Received Nasdaq notice of non-compliance with Listing Rule 5250(c)(1) for failure to timely file Q1 2026 Form 10-Q.
Q1 2026 revenue $2.15M (+34% YoY); net loss improved to $(165K) from $(737K) in Q1 2025.
BIO-key receives Nasdaq delisting notice; stock to move to OTC Markets on May 13
Nasdaq suspends BKYI trading after close May 12 for failing to maintain $1 bid price for 10 consecutive days by May 4 and late Form 10-K.
BIO-key announces 1-for-10 reverse stock split to regain Nasdaq compliance
Reverse stock split ratio set at 1-for-10, effective 5:00 p.m. ET on April 29, 2026; trading begins split-adjusted April 30, 2026.
BIO-key shareholders approve reverse stock split up to 1-for-10
Proposal approved with 4,209,160 votes for, 1,361,166 against, and 30,366 abstentions.
BIO-key receives Nasdaq non-compliance notice for delayed 10-K filing
Notice received April 16, 2026 for failure to timely file 2025 Form 10-K.
BIO-key expects 50% revenue growth to ~$5M and profitability in 1H 2026
1H'26 revenue expected ~$5M (+50% YoY vs $3.3M); positive net income vs $1.9M loss in 1H'25.
BIO-key reports FY2025 revenue $6.1M, net loss $4.6M; Q1'26 revenue up 37% YoY
FY2025 revenue $6.1M, down 12% YoY; net loss $4.6M ($0.69/sh) vs $4.3M ($2.09/sh) in 2024.
BIO-key secures $1.04M license renewal from foreign retail bank; cash at $2.7M
$1.04M one-year renewal from foreign retail bank (client since 2015), up 30% YoY.
BIO-key Q3 revenue falls 28% to $1.55M; net loss widens; raises $3.1M via warrant exercise
Q3 2025 revenue $1.55M (down 28% YoY); net loss ($964,849) or ($0.15) per share vs ($738,959) ($0.39) in Q3'24.
BIO-key receives Nasdaq extension to May 2026 to regain $1 bid price compliance
Nasdaq granted BIO-key an additional 180-day period, until May 4, 2026, to meet the $1.00 minimum bid price rule.
BIO-key raises $3.1M via warrant exercise, exchanges debt for equity
Gross proceeds $3.1M from exercise of 3,091,668 warrants at reduced exercise price of $1.02; new warrants for 6.18M shares at $1.02.
BIO-key closes $1.13M secured note with Streeterville Capital, net $1M for working capital
Issued $1.13M senior secured promissory note; net proceeds $1M after $125K OID and $5K transaction costs.
BIO-key shareholders approve 700k share increases to 2023 stock plan and ESPP
2023 Stock Incentive Plan share reserve raised by 700,000 to 1,033,334 shares.
BIO-key Q2 revenue up 49% to $1.7M; launches CyberDefense Initiative for defense contracts
Q2 revenue $1.70M vs $1.14M YoY; net loss improved to ($1.17M) or ($0.20)/share from ($1.67M) or ($1.00)/share.
BIO-key stockholders elect all director nominees and approve all proposals at 2025 annual meeting
Elected directors Michael DePasquale, Kelvin Wong, Robert Michel, Emmanuel Alia, Cameron Williams with ~1M votes each; broker non-votes of ~2.7M.
BIO-key Q1 rev $1.6M, net loss widens; Nasdaq bid price deficiency notice
Q1 2025 revenue $1.6M (-25% YoY); net loss $736k vs $510k; EPS ($0.16) vs ($0.32).
BIO-key regains Nasdaq compliance after late 10-K filing
Received Nasdaq non-compliance notice on April 17, 2025, for failure to timely file Form 10-K.
BIO-key narrows FY2024 net loss 49% to $4.3M on revenue of $6.9M (down 11%)
Net loss improved to $4.3M ($2.10/sh) from $8.7M ($15.21/sh) in 2023, reflecting higher gross margin and lower costs.
BIO-key raises ~$3.8M via warrant exercise; exchanges $834K debt for equity
Exercised 2,061,112 existing warrants at $1.85/share, gross proceeds ~$3.8M before fees.
BIO-key acquires 5M Boumarang shares from Fiber Food in exchange for 595K shares, adding $5M assets
BIO-key exchanged 595,000 shares of its common stock (19% of outstanding) for 5 million Boumarang shares valued at $5 million.
BIO-key swaps 19% equity stake for $5M Boumarang shares to regain Nasdaq compliance
Exchanged 595,000 shares (19% of outstanding) for 5M Boumarang shares valued at $5M ($1/share).
BIO-key Q3 revenue up 18% to $2.1M; net loss narrows to $0.7M from $1.8M
Revenue $2.1M vs $1.8M; license revenue rose 52% to $1.4M on expanded customer deployments.
BIO-key raises ~$1.9M via warrant exercise; issues new warrants to investor
Investor immediately exercised 1,030,556 existing warrants at reduced price of $1.85/share.
BIO-key annual meeting results: all director nominees elected, say-on-pay approved
Five director nominees elected with at least 349,187 votes for each; broker non-votes 667,346.
BIO-key Q2 2024 revenue down 42% YoY to $1.1M; net loss narrows to $1.7M
Q2 revenue $1.1M vs $1.9M YoY; delayed ~$450k software license fees and lower project services.
BIO-key issues $2.36M secured note to Streeterville Capital; net proceeds $2M for working capital
$2,360,000 principal senior secured note issued to Streeterville Capital; net proceeds $2,000,000 after OID and fees.
BIO-key Q1 revenue $2.2M, net loss narrows to $0.5M; generates positive operating cash flow
Revenue $2.2M flat YoY, up 19.5% QoQ; gross margin improved to 86.3% from 40% on higher license mix and prior hardware reserve.
BIO-key receives Nasdaq delisting notice for stockholders' equity below $2.5M
Nasdaq notified BIO-key on June 10, 2024 that stockholders' equity as of Dec 31, 2023 failed to meet the $2.5M minimum requirement.
BIO-key receives Nasdaq delisting notice for late 10-Q; restating prior periods
Received Nasdaq notice on May 22, 2024 for non-compliance with Listing Rule 5250(c)(1) due to late 10-Q filing for quarter ended March 31, 2024.
BIO-key replaces auditor Marcum with Bush & Associates after material weakness and restatement
Dismissed Marcum LLP as independent auditor on April 23, 2024; engaged Bush & Associates CPA on April 24, 2024.
Audit committee found errors in revenue recognition at Swivel Secure Europe for Q1-Q3 2023.
2023 revenue $9.1M (+29% YoY); net loss $(6.2M) vs $(12.2M) in 2022; EPS $(11.45).
BIO-key regains Nasdaq bid-price compliance after stock closes above $1.00 for 10 sessions
As of Jan 5, 2024, common stock closing bid price exceeded $1.00 for 10 consecutive business days.
Repaid $2.2M senior secured note held by AJB Capital Investments, eliminating all long-term debt.
Stockholders approved reverse split at ratio 1-for-6 to 1-for-20; Board set final ratio at 1-for-18.
BIO-key director Thomas E. Bush III resigns from board effective Nov 8, 2023
Thomas E. Bush III resigned from BIO-key's Board of Directors effective November 8, 2023.
BIO-key closes $3.75M public offering; net $3.3M to repay debt and for working capital
Gross proceeds $3.75M from sale of 21.43M units at $0.175/unit; each unit comprises one share (or pre-funded warrant) and one 5-year warrant exercisable at $0.175.
BIO-key Q3 revenue up 33% to $1.8M, net loss per share narrows to ($0.08) from ($0.29)
Revenue $1.8M (+33% YoY); gross profit $1.4M (+43%); gross margin 77% vs 71%.
BIO-key Q2 revenue flat at $1.9M; net loss narrows to $1.4M
Q2 revenue $1.9M flat YoY; first-half revenue up 29% to $5.9M.
BIO-key stockholders elect six directors, ratify auditor, approve say-on-pay at 2023 annual meeting
All six director nominees elected; Michael DePasquale received 2,257,370 For, 511,573 Withheld.
BIO-key receives additional 180-day Nasdaq compliance period until Jan 8, 2024 for bid price rule
Received deficiency letter on Jan 12, 2023 for bid price below $1.00 for 30 consecutive days.
BIO-key amends securities purchase agreement, waives defaults with AJB Capital
Amends Dec 2022 agreement: repurchase of up to 272k commitment shares if principal paid by July 22, 2023; up to 214k if paid by Aug 21, 2023, each for $1.00.
BIO-key cures Nasdaq listing deficiencies; all periodic reports now timely filed
Nasdaq notified BIO-key on June 13, 2023 that it is in compliance with Listing Rule 5250(c)(1).
BIO-key appoints Cameron E. Williams to Board of Directors and Audit Committee
Cameron E. Williams appointed to the Board effective June 2, 2023; also joins the Audit Committee.
BIO-key receives Nasdaq non-compliance notice for late filings; plan due June 20
Nasdaq notified BIO-key on May 23, 2023 of non-compliance for failing to timely file Form 10-Q for Q1 2023.
BIO-key Q1 revenue rises 59% to $3.1M; net loss narrows to $0.5M
Revenue $3.1M (+59% YoY); gross profit $2.3M (73% margin); net loss $0.5M vs $1.0M in Q1'22.
BIO-key receives Nasdaq non-compliance notice for late 10-K filing
Nasdaq notified BIO-key on April 18, 2023, of non-compliance with Listing Rule 5250(c)(1) due to failure to file annual 10-K for FY2022.
On November 8, 2023, Thomas E. Bush, III notified BIO-key International, Inc. (the “ Company ”) that he would be resigning from the Board of Directors of the Company effective November 8, 2023.
On June 2, 2023, Cameron E. Williams was appointed to serve on the Board of Directors (the “Board) of BIO-key International, Inc. (the “Company”).
On April 14, 2023, Pieter Knook notified BIO-key International, Inc. (the “Company”) that he would be resigning from the Board of Directors of the Company effective May 13, 2023.
On February 9, 2023, Thomas Gilley notified BIO-key International, Inc. (the “Company”) that he would be resigning from the Board of Directors of the Company effective February 9, 2023.
Max materiality 0.95 · Median 0.65 · Most common event other_material